Analysis of neuroanatomical differences in mice with genetically modified serotonin transporters assessed by structural magnetic resonance imaging

Jacob Ellegood1*, Yohan Yee1,4, Travis M. Kerr3, Christopher L. Muller3, Randy D. Blakely2,3,5, R. Mark Henkelman1,4, Jeremy Veenstra-VanderWeele2,6 and Jason P. Lerch1,4

Abstract

Background: The serotonin (5-HT) system has long been implicated in autism spectrum disorder (ASD) as indicated by elevated whole blood and platelet 5-HT, altered platelet and brain receptor and transporter binding, and genetic linkage and association findings. Based upon work in genetically modified mice, 5-HT is known to influence several aspects of brain development, but systematic neuroimaging studies have not previously been reported. In particular, the 5-HT transporter (serotonin transporter, SERT; 5-HTT) gene, Slc6a4, has been extensively studied.

Methods: Using a 7-T MRI and deformation-based morphometry, we assessed neuroanatomical differences in an Slc6a4 knockout mouse on a C57BL/6 genetic background, along with an Slc6a4 Ala56 knockin mouse on two different genetic backgrounds (129S and C57BL/6).

Results: Individually (same sex, same background, same genotype), the only differences found were in the female Slc6a4 knockout mouse; all the others had no significant differences. However, an analysis of variance across the whole study sample revealed a significant effect of Slc6a4 on the amygdala, thalamus, dorsal raphe nucleus, and lateral and frontal cortices.

Conclusions: This work shows that an increase or decrease in SERT function has a significant effect on the neuroanatomy in 5-HT relevant regions, particularly the raphe nuclei. Notably, the Slc6a4 Ala56 knockin alone appears to have an insignificant, but suggestive, effect compared to the KO, which is consistent with Slc6a4 function. Despite the small number of 5-HT neurons and their localization to the brainstem, it is clear that 5-HT plays an important role in neuroanatomical organization.

Keywords: Serotonin, Slc6a4, 5-HT, 5HTT, Magnetic resonance imaging, Neurodevelopment, Brain, Dorsal raphe nuclei

Background

The brain serotonergic system influences multiple processes during development and throughout life, including neurogenesis, programmed cell death, cell migration, dendritic and axonal development, synaptogenesis, and synaptic plasticity [1–4]. Serotonergic neurons are among the earliest in the brain to be specified for neurotransmitter phenotype and project from the raphe nuclei, which flank the midline along the rostral-caudal extension of the midbrain and brainstem [1–4]. Based on the distribution of the main projections from the raphe, two clusters of raphe nuclei can be defined, a rostral and a caudal group [1, 5–8]. The rostral group projects mainly to the forebrain and is composed of the caudal linear, the dorsal raphe, and median raphe nuclei. This rostral group accounts for 85% of all the serotonergic neurons in the brain [1]. The caudal group primarily projects to the brainstem, cerebellum, and spinal cord [1]. Relative to the rest of the cell bodies in the brain, which number in the billions, serotonin (5-HT) neurons...
account for approximately 1/1,000,000 of all neurons in the brain [9]. While this is a small portion of the overall brain neurons, the serotonergic neurons project throughout the brain, touching multiple systems.

The 5-HT system has been linked to several disorders, including, but not limited to, obsessive compulsive disorder (OCD), anxiety, depression, schizophrenia, Down syndrome, and autism spectrum disorder (ASD) [10]. In ASD, the disruption of the serotonergic system is one of the more consistent and well-replicated findings [11–13]. In fact, elevated blood 5-HT levels in a group of 50 children with autism was first reported in 1961 [14], and this hyperserotonemia in ~ 25% of autistic patients has been consistently reported [11, 15]. Of the 800+ genes that have been associated with autism [16, 17], there are several related to 5-HT signaling, including the antidepressant-sensitive 5-HT transporter (serotonin transporter, SERT; 5-HTT) gene (SLC6A4) [18] and the integrin β3 gene (ITGβ3) [19], a SERT-interacting protein that influences 5-HT levels in the periphery and in the brain [20–22]. SERT is the primary mechanism of 5-HT inactivation, responsible for reuptake of the neurotransmitter into the presynaptic 5-HT neuron, where it can be repackaged or metabolized [23]. Therefore, changes in SERT expression and function alter extracellular 5-HT levels and signaling at 5-HT receptors.

The SERT gene has been extensively studied in the human population, and over 20 different gene variants have been found [24], the most studied of which is the functional promoter length polymorphic repeat (5-HTTLPR) [18], which has also been linked recently in a study of amygdala cortex connections [25]. An additional functional variant includes a variable number of tandem repeats (VNTR) in intron 2 (STIn2) [26]. Overall results of those gene variants have been inconclusive; however, there appears to be mounting evidence for a linkage in the 17q11.2 region, which includes the SERT gene [27]. Regardless, it had been speculated that optimal Slc6a4 activity may need to be highly regulated [28], i.e., both high and low Slc6a4 activity could correlate with illness susceptibility. We would hypothesize, however, that changes in Slc6a4 function may lead to disparate or even opposing morphological changes throughout the brain. For instance, the loss of SERT causes disruptions in the organization of the barrel fields in the somatosensory cortex of the mouse [29].

In 1998, the first Slc6a4 knockout (KO) mouse was created [30], and in that study the authors confirmed that 5-HT levels were 60–80% decreased in the brainstem, frontal cortex, hippocampus, and striatum, likely due to diminished synthesis and recycling of 5-HT. Further, these mice demonstrate a 50% reduction in serotonergic cell number in the dorsal raphe nucleus [31]. Slc6a4 KO mice display increased anxiety-like behaviors, reduced aggression, and exaggerated stress responses [32]. Despite adult brain expression being limited to 5-HT neurons, SERT is transiently expressed in a number of sensory regions as well as in the prefrontal cortex. Accordingly, disruption of SERT function during development has been linked to changes in the architecture and function of the somatosensory cortex and the medial prefrontal cortex [29, 33–35].

Linkage findings in autism spectrum disorder pointed to the chromosome 17q11 region that contains the SERT gene, and multiple amino acid variants in the SERT gene, including Gly56Ala, which increase 5-HT uptake, have been identified in the families with the strongest evidence of linkage [27]. A Slc6a4 Ala56 knockin (KI) mouse was created and initially found hyperserotonemia, altered CNS 5-HT system function, and changes in social and repetitive behaviors [36]. To examine the effects of genetic background, these animals were backcrossed from the initial 129S6 inbred strain to the C57BL/6 inbred strain frequently used for behavioral experiments [37]. Multiple phenotypes were sensitive to different backgrounds. Additionally, neuroanatomy has also been found to be sensitive across inbred strains [38].

With the long-standing association between 5-HT and autism and the well-described effects of 5-HT on neurodevelopment, it is perhaps surprising that the direct relationship between 5-HT and mesoscopic morphological changes throughout the brain has not been systematically investigated. Volume differences in several mouse models related to both autism and the 5-HT system have been examined previously, including an Itgb3 KO, which encodes a SERT-binding partner [39]. Also, a recent investigation of 26 mouse models related to autism revealed that the neuroanatomical differences clustered into three distinct groups with similar neuroanatomical phenotypes [40]. While that study includes the male animals from the Slc6a4 KO and Slc6a4 Ala56 KI models, that paper did not examine the individual models in detail but only the similarities and differences across multiple autism-related mouse models. Given the effect these genetic manipulations on 5-HT levels in the two different models, we hypothesize that changes in brain structure may occur as a direct result of differing levels of serotonin fiber projections brought about by the manipulation. Therefore, the purpose of the current study is to examine, in detail, the specific neuroanatomical differences caused by the different Slc6a4 mutations.

Methods
Mice
Three different mouse lines were used in this study: (1) homozygous Slc6a4 knockout mice (Slc6a4 KO) and control animals (C57Bl6/J) were purchased directly from The Jackson Laboratory (JAX #008355, B6.129(Cg)-Slc6a4^tm1Kpl/J) and JAX #000664, C57Bl6/J), (2) and (3)
**Slc6a4** Ala56 knockin (KI) mice on different inbred strain backgrounds, namely C57BL/6J (B6) and 129S6/SvEvTac (129). **Slc6a4** Ala56 KI mice were created as previously described [28, 36], and their colony was maintained in Vanderbilt University in Nashville, TN, USA. In total 121 mice were examined in this study. Thirty-nine were in the **Slc6a4** KO group, 19 wild-type (WT, 9M and 10 F) and 20 **Slc6a4** KO (10M, 10F); 40 were in the **Slc6a4** Ala56 KI (B6) group, 20 WT (10M and 10F) and 20 **Slc6a4** Ala56 KI (10M and 10F); and 42 were in the **Slc6a4** Ala 56 KI (129) group, 21 WT (11M and 10F) and 13 **Slc6a4** Ala56 KI (11M and 10F). All experimental mice were 60 ± 2 days old.

**Perfusions**

Perfusions were either performed on site at the Mouse Imaging Centre (MICe) in Toronto, ON, Canada, for the **Slc6a4** KO mice, or at Vanderbilt University prior to being shipped overnight to MICe. The details of the perfusion protocol have been previously discussed at length [41, 42]. Briefly, mice are anesthetized with a ketamine/xylazine mix or pentobarbital and then intercardially perfused with 30 mL of 0.1 M PBS containing 10 U/mL heparin and 2 mM ProHance (Bracco Diagnostics Inc., a gadolinium contrast agent) followed by 30 mL of 4% paraformaldehyde (PFA) also containing 2 mM Prohance. After perfusion the mouse was decapitated and the skin, ears, and lower jaw were removed. The brain is left within the skull to minimize any deformations and is first incubated in the 4% PFA/Prohance solution overnight. Then, prior to scanning, the brain was incubated for an additional 7 days, at a minimum, in a solution of PBS, 2 mM ProHance, and 0.02% sodium azide, in order to equalize the contrast agent.

**Magnetic resonance imaging**

A 7.0-T MRI scanner (Agilent Inc.) was used to acquire all images. For the anatomical scan, a 40-cm inner bore diameter gradient was used (max gradient 30 G/cm) in conjunction with a custom-built solenoid coil array to image 16 samples in parallel [42, 43].

**Anatomical scan**

In order to assess the volume differences throughout the brain, a T2-weighted 3D fast spin echo (FSE) sequence was used and is designed for optimized gray/white matter contrast. The sequence parameters for this scan are as follows: TR = 2000 ms, echo train length = 6, echo spacing = 10 ms, with the center of k-space acquired on the fourth echo, TEeff = 42 ms, field of view (FOV) 14 mm × 28 mm × 25 mm, and a matrix size of 250 × 504 × 450, which yields an isotropic (3D) resolution of 56 μm. In the first phase encode dimension, consecutive lines of k-space were assigned to alternating echoes to move discontinuity-related ghosting artifacts to the edges of the FOV [44]. This sequence, therefore, involves an oversampling of k-space in the phase encode direction by a factor of 2 to avoid the interference of ghosting artifacts in the main image, which yields a FOV of 28 mm that is subsequently cropped to 14 mm after reconstruction. Total imaging time for this sequence was 11.7 h.

**Registration and analysis**

Deformation-based morphometry (DBM) was used to analyze the volume differences throughout the brain. DBM was performed by registering the mouse brains together through a series of linear (6 parameter fit followed by a 12 parameter fit) and nonlinear fits. After the registration pipeline, all scans are then resampled with the appropriate transform and averaged to create a population atlas representing the average anatomy of the study sample. All registrations were performed with a combination of mni_autoreg tools [45] and advanced normalization tools (ANTs) [46, 47]. The result of the registration is to have all the scans deformed into alignment with each other in an unbiased fashion. This allows for the analysis of the deformations required to take each individual mouse’s anatomy into the final atlas space. The goal is to model how the deformation fields relate to the genotype [48, 49]. The Jacobian determinants of the deformation fields are then used as measures of volume at each voxel. The quantification of the absolute and relative DBM changes are measured from these Jacobians, including the diffeomorphic alignment plus the affine changes for the absolute volume calculation and the diffeomorphic warp alone for the relative volumes. Regional volume differences are then calculated by warping a pre-existing classified MRI atlas onto the population atlas, which allows the calculation of regional volumes across the brain. The classified MRI atlas includes 159 different structures and incorporates three separate pre-existing atlases: (1) delineates 62 different structures throughout the brain including subcortical white and gray matter structures, corpus callosum, striatum, and thalamus [50]; (2) further divides the cerebellum into its various regions, individual lobules, white and gray matter, and the deep cerebellar nuclei [51]; and (3) divides the cortex into 64 different regions, including areas of the cingulate cortex and primary motor and somatosensory cortices [52]. The total brain volume and seven summary regions are also assessed including the cortex (as a whole), cerebellum, ventricles, brainstem, olfactory bulbs, cerebral white matter, and cerebral gray matter. Multiple comparisons were controlled for using the false discovery rate (FDR) [53].

**Additional Slc6a4 comparisons**

As the *Slc6a4* Ala56 KI mice and *Slc6a4* KO mice were acquired from different colonies (Jackson Labs for the
Slc6a4 KO mice and Vanderbilt University for the Slc6a4 Ala56 KI mice), in order to assess the effect of Slc6a4 across all the mice in this study, we needed to normalize one of the studies to the other using the WT C57Bl6/J mice, since this would account for colony effects between groups. This was done by calculating the differences in the C57Bl6/J WT from the Slc6a4 Ala56 KI (B6) group acquired from Vanderbilt and the C57Bl6/J WT from Jackson Labs. After the standardization (beta) coefficient was calculated between the two WT groups during the registration process, the calculated 3D scalar value was applied to the full Slc6a4 KO group (WT and Slc6a4 KO mice) used in this study to normalize that group to the Slc6a4 Ala56 KI groups. That normalization applied to the Slc6a4 KO mice takes into account colony effects between sites and allows a comparison across all mice in this study to determine the variance caused by the Slc6a4 gene. Variance in the Slc6a4 gene was assessed across groups using an ANOVA and co-varying for sex and background (~Background + Sex + Genotype).

Assessment of the dorsal raphe nucleus (DRN) connectivity

To determine whether the Slc6a4 neuroanatomical phenotype is consistent or related to specific fiber tracts projecting out of the DRN, we compared the absolute F-statistic map with neuronal projection data from the Allen Institute [54, 55] after aligning our dataset to the Allen Institute’s Common Coordinate Framework (CCFv3) reference atlas (http://mouse.brain-map.org/static/atlas).

Projection density data derived from 3D, high resolution, whole-brain two-photon microscopy images of neuronal tracers injected into a variety of brain regions were obtained from the Allen Institute’s publicly available API. Specifically, this data is from mouse brains injected with a recombinant adeno-associated viral anterograde tracer that expresses EGFP. Original resolution data is gridded at 50 μm and summarized as the number of voxels within the 50-μm grid that contained a tracer signal (“projection density”). Since data from the connectivity experiments are obtained by injecting only in the right hemisphere, whereas volume changes are bilateral, bilateral fiber tract connectivity is estimated by reflecting each 3D tracer dataset across the sagittal midline plane and merging the data with its mirrored pair by taking the maximum projection density value at each voxel. Of the connectivity experiment datasets downloaded, five consisted of the DRN as the primary injection structure. These five experiments are further merged together by taking the maximum projection density value at each voxel. To determine the association between volume differences and DRN-related connectivity, the absolute F-statistic map, taken from the assessment of the variance in the Slc6a4 gene, is thresholded at an FDR of q < 0.05 (F > 4.56) and compared with the merged DRN projection density image that was thresholded at 0.1. All voxelwise analyses were carried out within a mask of the whole brain but excluded voxels in the seed region to avoid selection bias.

Results

The first assessment for differences in neuroanatomy was the total brain volume, in which no differences were found in the Slc6a4 Ala56 KI mice. This was true for the full group, males or females separately, and on both backgrounds (B6 or 129). On the other hand, the Slc6a4 KOs had a smaller total brain volume for the full group (448 ± 17 mm^3 for KO versus 462 ± 15 mm^3 for the WT B6, q = 0.04, where q is the FDR-corrected p value), largely driven by the female mice (439 ± 10 mm^3 for KO versus 459 ± 19 mm^3 for WT, q = 0.03), whereas the male-only group had no significant difference in total brain volume (457 ± 18 mm^3 for KO versus 466 ± 10 mm^3 for WT, q = 0.66) (see Fig. 1). Assessment of the seven summary regions revealed that the total brain volume difference that we were seeing in the full group of Slc6a4 KO mice was driven largely by the cortex (~3.8%, q = 0.02) and cerebellum (~3.5%, q = 0.01). While the whole brain volume of the female mice was found to be significantly smaller, the female Slc6a4 KO mice had additional differences in the olfactory (~4.3%, q < 0.05) cerebral gray (~4.1%, q < 0.05) and white matter (~4.5%, q = 0.04) regions. Figure 1 highlights the differences in these summary regions across groups, which includes the normalized Slc6a4 KO group for comparison. When the relative volume of the summary regions is examined (i.e., each region is measured as a percentage of total brain volume), no significant differences were found. Therefore, the differences we observed in the female Slc6a4 KO mice indicate that the brains are almost uniformly smaller.

Of the 159 regions examined, no significant differences were found in the Slc6a4 Ala56 KI mice (Fig. 2). This was seen in the full group or individually in the males and females and was measured with either absolute or relative volume and compared to their corresponding WT. There were, however, some regions within the cerebellum, specifically in the gray matter of the cerebellar vermis, that had trends towards an increase compared to WT with p values less than 0.05, but these results did not survive the correction for multiple comparisons (Fig. 2). In the Slc6a4 KO mice, we see 47 out of the 159 regions have absolute volume differences compared to WT in the full group; again, this is driven primarily by the females, which have 69 regional differences while the males have 0. The smaller regions in the female mice are located in the cortex, specifically in the piriform, auditory, temporal association, and entorhinal cortices, as well as large scale
decreases throughout the cerebellum (Fig. 2). Despite the lack of findings for the female \textit{Slc6a4} KO mice with relative volume in the summary regions, there were specific areas where differences were found, including the auditory, ectorhinal, and entorhinal cortices as well as the cortical amygdaloid area (Fig. 2). Furthermore, increases in relative volume were found in the cerebral peduncle and lateral septum.

Voxelwise analysis also found no significant differences between the two \textit{Slc6a4} Ala56 KI mice and their WT counterparts on either background. This was true for both absolute and relative volume measures. Similar to the regional findings, the full group of \textit{Slc6a4} KO mice on the B6 background highlighted several areas of significance. Figure 3 shows the significant voxelwise differences in both absolute and relative volume in the \textit{Slc6a4} KO. Absolute volume decreases were seen in the lateral cortex, amygdala, and areas of the thalamus, and relative volume increases were seen in the lateral septum and thalamus.

Further assessment of the variance across all groups, after normalization of the \textit{Slc6a4} KO group (see the “Methods” section), revealed several areas affected both voxelwise and regionally. Figure 4 shows the significant differences due to the \textit{Slc6a4} gene assessed by an ANOVA while factoring in both the background strain and sex. Four different example voxels are shown on the left (Fig. 4a–d): lobule X, the dorsal raphe, temporal association cortex, and the amygdala. The voxelwise differences recapitulate the differences seen in Fig. 3 but also add a number of new areas of interest, particularly in the colliculi and more widespread differences in the orbital frontal cortex, thalamus, and hypothalamus (see Additional file 1: Table S1 for a full listing of the absolute and relative volume differences seen in Fig. 4). A specific region of interest, relevant to the serotonin system, is the dorsal raphe nuclei, not included in our regional atlas but clearly highlighted.

Figure 5 shows comparisons between the volume differences assessed in Fig. 4 and the neuronal projection data for the DRN from the Allen Institute. A comparison of the \textit{F}-statistic map showing \textit{Slc6a4} volume differences and projections from the DRN (Fig. 5a, columns ii and iii) shows that anterograde
projections overlap significant $F$-statistic voxels for some frontal cortex areas; however, for most other regions, projections come near to, but do not overlap with regions that show significant differences in volumes (Fig. 5 column iv). Specifically, the amygdala, anterior hypothalamus, and auditory areas of the temporal cortex, along with the superior colliculus, contain significant volumetric differences and have projections from the DRN nearby but do not overlap.
**Discussion**

Gain of function SERT manipulations is thought to have a minimal effect on the anatomy of the brain [56]. It has, however, been shown previously that mice with behavioral phenotypes also feature neuro-anatomical phenotypes in 87% of cases [57]. Therefore, there is often an expectation that known behavioral findings will be matched by a mesoscopic anatomical difference. The Slc6a4 Ala56 KI mice have differences in ultrasonic vocalizations (increased for B6 background, decreased for 129) and social interaction, as assessed by the three chamber tests (129S6) [36, 37]. The Slc6a4 KO mice have increased anxiety, increased stress, decreased aggression, increased acoustic startle, decreased exploratory behavior, and decreased motor agility [32, 58]. Due to the known behavioral phenotypes, robust neuroanatomical findings were expected across the models. Additionally, as MRI findings tend to be very sensitive, with several studies showing replications across labs (BTBR [59, 60], Neuroligin3 R451C knockin [61, 62]), and differentially created models (16p11.2 CNV [63, 64]), the relatively modest neuroanatomical findings due to modifications in the SERT gene were unexpected.
A recent examination of 26 different mouse models of autism, which included gene deletions, modifications, and duplications, noted that 70%, or 18 of the 26 models examined, were found to have either a significant relative or absolute volume difference [40]. While it should be noted that the data from the male mice used in this study were the same as the Slc6a4 KO and Slc6a4 Ala56 KI mice used in that study, none of the female mice used here were included. With 800+ genes associated with autism [16, 17], there are bound to be some null results or undetectable differences at the mesoscopic scale used in this work. The MRI analysis performed here is not at cellular resolution; therefore, any differences at a microscopic scale or the cellular level would be undetectable at the 56-μm isotropic voxel size used. This includes the known deficits in the organization and differentiation of the Slc6a4 KO somatosensory whisker barrel cortex [65]; no differences were found in the somatosensory cortex in any sex, measure, or model, which highlights a known functional/organizational difference that is undetectable by volume at the mesoscopic scale of the MRI.

The Slc6a4 Ala56 KI mutation by itself has no effect on the mesoscopic neuroanatomy, only trends, since no significant differences were found on either background in either absolute or relative volume when compared to its own wild-type. The Slc6a4 Ala56 KI mutation is a gain of function mutation that causes hyperserotonemia, more so on the 129 backgrounds than B6 [36]. It was also noted that the 5-HT levels in the Slc6a4 Ala56 KI (129) midbrain and forebrain were unchanged [36], which was not true in the Slc6a4 KO where there was a reduction.

Fig. 5 Association between the dorsal raphe nucleus (DRN) fiber-tract connectivity and SERT volume differences. a Shown in vertical panels are coronal slices through the mouse brain from anterior (top row) to posterior (bottom row), see top right of figure for location of slices relative to brain. Vertical panel columns correspond to i) anatomy (via MRI), ii) absolute volume differences (F-statistic), iii) neuronal tracers projecting anterograde from the dorsal raphe nucleus, and iv) voxels which show significant differences at a FDR q < 0.05 (F > 4.56) that also express a tracer signal.
in intracellular tissue 5-HT level throughout the brain and in serotonergic cell number in the dorsal raphe nucleus [31]. Therefore, it is likely that the Ala56 KI alone does not produce an Slc6a4 difference large enough to modify neuroanatomy to a detectable degree with the current methodology. As 5-HT is necessary for early brain development [29], there is also the possibility that at postnatal day 60 we are missing early brain developmental differences. Therefore, a longitudinal investigation would be beneficial to track brain development to see if the developmental trajectories are modified by the changes in Slt6a4 function. Importantly, it was recently shown that maternal Ala56 genotype impacts forebrain 5-HT levels and thalamocortical projections during midgestation [66], with no observed differences driven by embryo genotype. The Slc6a4 Ala56 KI animals studied here derive from heterozygous dams and sires so that WT and Slc6a4 Ala56 KI animals could be generated from mothers of the same genotype. This suggests that future studies should examine the impact of the maternal 5-HT system, which was held constant in this study by the use of heterozygous crosses to generate homozygous Slc6a4 Ala56 KI mice and wild-type littermate controls.

Regardless of the lack of findings individually for the Slc6a4 Ala56 KI, Fig. 4 clearly shows there is a significant effect of modifying the Slc6a4 gene on neuroanatomy across all models used here. The Slc6a4 Ala56 KI model, which is a gain of function mutation, has the opposite effect of the Slc6a4 KO mutation in several areas throughout the brain (Fig. 4). For example, the dorsal raphe nucleus, the heart of serotonin function in the brain, trends towards an increase in size for the Slc6a4 Ala56 KI and decreased for the Slc6a4 KO (Fig. 4b) but is significant across the entire study. Therefore, we would speculate that a gain or loss in function of SERT corresponds to a gain or loss in volume in several regions in brain, likely originating with the dorsal raphe. In rats and non-human primates, it has been shown that the efferent projections from the rostral group of the raphe nuclei, which includes the dorsal raphe nucleus, ascend through the internal capsule to the lateral cortex and additionally travel through the medial forebrain bundle to the hypothalamus, basal forebrain, and amygdala [1, 5–8]. The internal capsule is also significantly affected by genotype (F = 6.55, q < 0.01), as well as a large area in the lateral cortex (Fig. 4). Similarly, the hypothalamus (F = 4.05, q = 0.04), basal forebrain (F = 6.37, q = 0.01), and amygdala (F = 9.54, q = 0.001) are also significantly affected by genotype. This indicates that the changes to the Slc6a4 gene have an impact on the targets of projections from the rostral group of the raphe nuclei. The differences seen here in opposing directions for the Slc6a4 Ala56 KI versus the Slc6a4 KO in several regions (Fig. 4), additionally, are consistent with recently published work showing that these genotypes have opposing functional and developmental effects in the gut [67].

These findings were examined further by comparing our volumetric findings with neuronal projection data from the DRN. It was expected that there would be an overlap between the volume differences seen (Figs. 4 and 5ii) with the projection density images of the neuronal tracer seen in Fig. 5iii. While some areas did show overlap, particularly in the frontal cortical regions, for most areas, the tracer appears to come near to the volumetric differences but does not overlap directly, potentially reflecting the role of 5-HT as a morphogen acting via broader diffusion or volume transmission during development [68, 69]. The DRN projections do, however, project towards several of the affected regions albeit not within them, as visualized by the Allen Brain Atlas data. It is possible, therefore, that the differences in SERT in the DRN in both the Slc6a4 KO and Slc6a4 Ala56 KI are in fact causing these volumetric differences in the adjacent regions through this projection.

Of additional interest was the finding of a stronger neuroanatomical phenotype in the female Slc6a4 KO mice, and to a lesser insignificant extent in the Slc6a4 Ala56 KI mice, compared to the males. The stronger phenotype in the females is intriguing, and it seems to match up well with a study that reported an increase in 5-HT levels in female rats compared to their male counterparts [70]. This higher level of 5-HT in the females could possibly make them more susceptible to the knockout or knockin of SERT function. This highlights the necessity for investigation of both male and female mice in these types of studies and also lends additional weight to the recent NIH insistence of inclusion of both sexes in biomedical research [71]. Our volumetric findings in females contrast with a previous report that heterozygous male and female Slc6a4 KO mice (+/−) have increased brain mass, normalized to body mass, compared to controls at 8–12 weeks [72]. It is difficult to compare such different methodological approaches, since the disparity could be driven by genotype differences (+/− versus −/−), differences in age, differences driven by body mass, weight versus volumetric analyses, or removal of the brain from the skull versus in skull neuroimaging.

Future work could benefit from the examination of neuroanatomical differences at earlier timepoints, whether done longitudinally or as a cross-sectional study. Further, examination of the effects of maternal genotype, or maternal-offspring genotype interactions, could reveal broader effects on neurodevelopment due to in utero effects. It would also be worth examining additional genetic modifications of the Slc6a4 gene to see if they follow a similar pattern to what is shown here with increasing brain volume with increase 5-HT uptake.
The Slc6a4 Aal56 KI variant was found to have a ~30% increase in 5-HT uptake, but there are additional variants that have up to ~70% increases [28, 73]. Therefore, it may be beneficial to see if further increases in the areas mentioned here could be found in these other variants. Similarly, one could also examine the heterozygous Slc6a4 KO, which may show an intermediate loss of volume compared to WT.

There were a few limitations to this study: (1) It has been shown previously in the literature that there are differential effects of the SERT manipulation on the behavior in these different models. Therefore, this implies that there is likely no correlation between the behavior deficits and the neuroanatomical differences seen here. However, since behavior was not tested in these individual mice, this was beyond the scope of this current work. (2) The control animals used for the Slc6a4 KO mice were not the ideal controls for this work. The Slc6a4 KO mice were purchased directly from Jackson Laboratory (JAX #008355), and at that time they were bred either homozygote × homozygote or heterozygous × homozygous, both of which do not allow wild-type littermates. Therefore, for controls, C57BL6/J mice were used as suggested from Jackson Labs. Ideally, one would want to breed heterozygote × heterozygote in order to get WT littermates for comparison. However, the differences, only seen in females, do seem to indicate that C57BL6/J is a reasonable control neuroanatomically.

Conclusions
As suggested previously, this work shows that the SERT activity does contribute to adult neuroanatomy. An increase or decrease in the Slc6a4 function can cause a differential effect on the neuroanatomy in 5-HT relevant regions, particularly in the raphe nuclei. Considering the small number of 5-HT neurons found within the brain and the localization of those neurons, it is clear that serotonin function can be an integral part of the neuroanatomical organization.

Acknowledgements
We thank the Allen Institute for Brain Science for providing connectivity (©2011 Allen Institute for Brain Science. Allen Mouse Brain Connectivity Atlas. Available from: connectivity.brain-map.org) data used in this study.

Funding
This work was funded by the Canadian Institute for Health Research (CIHR), the Ontario Brain Institute (OBI), and the U.S. National Institutes of Health (MH094604 to JV). JE received salary support from the Ontario Mental Health Foundation (OMHF).

Availability of data and materials
The analysis packages used in this study can all be found on https://github.com/mouse-imaging-centre/. All datasets generated and R Code used during the current study are hosted on the mouseimaging.ca website (repo.mouseimaging.ca/repo/jacob/RSession_SERT.zip) and available from the corresponding author upon request. Additionally, in conjunction with the Ontario Brain Institute, we have been releasing our published data publicly through Brain-Code (http://repo.mouseimaging.ca/repo/jacob/RSession_−SERT.zip). All of the SERT data can be downloaded from there as well as additional mouse models we have examined.

Authors’ contributions
JE, TMK, and CLM perfused and prepared all the tissue for MRI scanning. JE imaged and analyzed all the MRI data. YY performed the connectivity analysis using data from the Allen Brain Institute. JE, JPL, RMH, JV, and RB conceived and designed the study. JE wrote the manuscript with contributions from all authors. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
The animal care committees at Vanderbilt University and the Toronto Centre for Phenogenomics approved all these experiments.

Consent for publication
Not applicable

Competing interests
JV has received research funding from Seaside Therapeutics, Novartis, Roche Pharmaceuticals, Forest, Sunovion, and SynapDx and has consulted for or served on advisory boards for Novartis, Roche, and SynapDx. The remaining authors declare no conflicts of interest.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Mouse Imaging Centre (MiCe), Hospital for Sick Children, 25 Orde Street, Toronto, Ontario M5T 3H7, Canada. 2Department of Pharmacology, Vanderbilt University, Nashville, TN 37235, USA. 3Department of Psychiatry, Vanderbilt University, Nashville, TN 37235, USA. 4Department of Medical Biophysics, University of Toronto, Toronto, ON M5S, Canada. 5Department of Biomedical Science and Brain Institute, Florida Atlantic University, Jupiter, FL 33451, USA. 6Department of Psychiatry, Columbia University, New York, NY 10027, USA.

Received: 12 December 2017 Accepted: 21 March 2018
Published online: 10 April 2018

References
1. Hornung J-P. The human raphe nuclei and the serotonergic system. J Chem Neuroanat. 2003;26:331–43.
2. Lauder JM, Krebs H. Serotonin as a differentiation signal in early neurogenesis. Dev Neurosci. 1978;1:15–30.
3. Chubakov AR, Gromova EA, Konzalov GY, Sarkisova EF, Chumakov EI. The effects of serotonin on the morpho-functional development of rat cerebral neocortex in tissue culture. Brain Res. 1986;369:285–97.
4. Chubakov AR, Tsyganova VG, Sarkisova EF. The stimulating influence of the raphé nuclei on the morphofunctional development of the hippocampus during their combined cultivation. Neurosci Behav Physiol. 1993;23:271–6.
5. Steinbusch HW, van der Kooy D, Verhoofstad AA, Pellegrino A. Serotonergic and non-serotonergic projections from the nucleus raphe dorsalis to the caudate-putamen complex in the rat, studied by a combined immunofluorescence and fluorescent retrograde axonal labeling technique. Neurosci Lett. 1980;19:137–42.

6. van der Kooy D, Kypers HG. Fluorescent retrograde double labeling: axonal branching in the ascending raphe and nigral projections. Science. 1979;204:873–5.

7. van der Kooy D, Hatton T. Dorsal raphe cells with collateral projections to the caudate-putamen and substantia nigra: a fluorescent retrograde double labeling study in the rat. Brain Res. 1980;186:1–7.

8. Kievet J, Kypers HG. Subcortical afferents to the frontal lobe in the rhesus monkey studied by means of retrograde horseradish peroxidase transport. Brain Res. 1975;85:261–6.

9. Jacobs BL, Azmitia EC. Structure and function of the brain serotonin system. Physiol Rev. 1992;72:165–229.

10. Sodhi MS, Sanders-Bush E. Serotonin and brain development. Int Rev Neurobiol. 2004;59:111–74.

11. Muller CL, Anacker AM, Veenstra-VanderWeele J. The serotonin system in autism spectrum disorder from biomarker to animal models. Neuroscience. 2016;321:24–41.

12. Yang C-J, Tan H-P, Du Y-J. The developmental disruptions of serotonin signaling may involved in autism during early brain development. Neuroscience. 2014;267:1–10.

13. Whitaker-Azmitia PM. Behavioral and cellular consequences of increasing serotonergic activity during brain development: a role in autism? Int J Dev Neurosci. 2005;23:75–83.

14. SCHAIN RJ, FREEDMAN DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr. 1961;58:315–20.

15. Cook EH, Lenthal BL. The serotonin system in autism. Curr Opin Pediatr. 1996;8:348–54.

16. Banerjee-Basu S, Packer A. SFARI gene: an evolving database for the autism spectrum disorders (ASDs). Mol. Autism. 2013;4:36.

17. Abrahams BS, Arking DE, Campbell DB, Mefford HC, Morrow EM, Weiss LA, et al. Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. Proc Natl Acad Sci U S A. 2005;102:5528–9.

18. Veenstra-VanderWeele J, Muller CL, Iwamoto H, Sauer JE, Owens WA, Shah CR, et al. Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. J Neurosci. 2013;33:1118–25.

19. Weiss LA, Kosova G, Delahanty RJ, Jiang L, Cook EH, Ober C, et al. Evidence of linkage between the serotonin transporter and autistic disorder. Mol Psychiatry. 1997;2:247–50.

20. Weiss LA, Kosova G, Delahanty RJ, Jiang L, Cook EH, Ober C, et al. Variation in 5HT6B3 is associated with whole-blood serotonin level and autism susceptibility. Eur J Hum Genet. 2006;14:923–31.

21. Camero AMD, Blakely HD. Serotonin, protein kinase C-, and -S-associated redistribution of the platelet serotonin transporter. J Biol Chem. 2006;281:24679–60.

22. Herrmann MU, Hutter T, Muller F, Muhlbberger A, Paul P, Reif A, et al. Additive effects of serotonin transporter and tryptophan hydroxylase-2 gene variation on emotional processing. Cereb Cortex. 2007;17:1163–130.

23. Weiss LA, Ober C, Cook EH. ITG83 shows genetic and expression interaction with SLC6A4. Hum Genet. 2006;120:93–100.

24. Murphy DL, Fox MA, Timpano KR, Moya PR, Ren-Patterson R, Andrews AM, et al. The influence of the serotonin transporter story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology. 2008;55:93–60.

25. Huang CH, Santangelo SL. Autism and serotonin transporter gene polymorphisms: a systematic review and meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:903–13.

26. Velazquez F, Wiggins J, Duran MN, Martin LM, Duman RS. The influence of 5-HTTLPR transporter genotype on amygdala-subgenual anterior cingulate cortex connectivity in autism spectrum disorder. Dev Cogn Neurosci. 2017;24:12–20.

27. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:1527–31.

28. Suttcliffe JS, Delahanty RJ, Prasad HC, McCalley JI, Han Q, Jiang L, et al. Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. Am J Hum Genet. 2005;77:265–79.

29. Veenstra-VanderWeele J, Jessen TN, Thompson BJ, Carter M, Prasad HC, Steiner JA, et al. Modeling rare gene variation to gain insight into the oldest biomarker in autism: construction of the serotonin transporter Gly56Ala knock-in mouse. J Neurodev Disord. 2009;1:158–71.

30. Chen X, Ye R, Gargus JJ, Blakely RD, Dobrenis K, Sze JY. Disruption of transient serotonin accumulation by non-serotonin-producing neurons impair cortical map development. Cell Rep. 2015. https://doi.org/10.1016/j.celrep.2014.12.033. (Pub ahead of print).

31. Bengel D, Murphy DL, Andrews AM, Wilmchens CH, Feltner D, Heils A, et al. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ("ecstasy") in serotonin transporter deficient mice. Mol Pharmacol. 1998;53:649–55.

32. Lira A, Zhou M, Castanon N, Anzorge MS, Gordon JA, Francis JH, et al. Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. BPS. 2003;54:960–71.

33. Holmes A, Lit Q, Murphy DL, Gold E, Crawley JN. Abnormal anxiety-related behavior in serotonin transporter null mutant mice: the influence of genetic background. Genes Brain Behav. 2003;2:365–80.

34. Rebello TJ, Yu Q, Goodfellow NM, Caffey Caglioastrico MK, Teissier A, Morelli E, et al. Postnatal day 2 to 11 constitutes a 5-HT-sensitive period impacting adult mPFC function. J Neurosci. 2014;34:12579–93.

35. Ellegood JS, Delahanty RJ, Prasad HC, McCauley JL, Han Q, Jiang L, et al. Altered background modulates phenotypes of serotonin transporter Ala56 knock-in mice. Mol. Autism. 2013;4:35.

36. Scholz J, Lalliberté C, van Ende M, Lerch JP, Henkelman MR. Variability of brain anatomy for three common mouse strains. Neuroimage. 2016;142:566–62.

37. Ellegood J, Henkelman RM, Lerch JP. Neuroanatomical assessment of the integrin β3 mouse model related to autism and the serotonin system using high resolution MRI. Front Psychiatry. 2013;2:37.

38. Ellegood J, Anagnostou E, Babineau BA, Crawley JN, Lin L, Genetiste M, et al. Clustering autism: using neuroanatomical differences in 26 mouse models to gain insight into the heterogeneity. Mol Psychiatry. 2015;20(1):118–25. https://doi.org/10.1038/mp.2014.198. Epub 2014 Sep 9.

39. Cahill LS, Lalliberté CL, Ellegood J, Spring S, Gleave JA, Ede MC, et al. Preparation of fixed mouse brains for MRI. NeuroImage. 2012;60:933–9.

40. Lerch JP, Sed SG, Henkelman RM. MRI phenotyping of genetically altered mice. Methods Mol Biol. 2011;711:349–60.

41. Dazzal S, Spring S, Cahill LS, Henkelman RM. Multiple-mouse neuroanatomical magnetic resonance imaging. J Vis Exp. 2011;(48). https://doi.org/10.3791/2487.

42. Thomas DL, De Vita E, Roberts S, Turner R, Yousay TA, Oddie R. High-resolution fast spin echo imaging of the human brain at 4.7 T: implementation and sequence characteristics. Magn Reson Med. 2004;51:1254–64.

43. Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr. 1994;18:192–205.

44. Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Am. 2008;26:12–41.

45. Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage. 2011;54:2033–44.

46. Lau JC, Lerch JP, Sed SG, Henkelman RM, Evans AC, Bedell BJ. Longitudinal neuroanatomical changes determined by deformation-based morphometry in a mouse model of Alzheimer’s disease. Neuroimage. 2008;42:19–27.

47. Niemunis BJ, Frenkenen AM, Adamson SR, Henkelman RM, Sed JG. Anatomical phenotyping in the brain and skull of a mutant mouse by magnetic resonance imaging and computed tomography. Physiol Genomics. 2006;24:154–62.

48. Dorr AE, Lerch JP, Spring S, Kaban N, Henkelman RM. High resolution three-dimensional brain atlas using an average magnetic resonance image of 40 adult C57Bl/6J mice. Neuroimage. 2008;42:620–9.
51. Steadman PE, Ellegood J, Szulc KU, Turnbull DH, Joyner AL, Henkelman RM, et al. Genetic effects on cerebellar structure across mouse models of autism using a magnetic resonance imaging atlas. Autism Res. 2014;7:124–37.

52. Ullmann JFP, Watson C, Janke AL, Kurniawan ND, Reuters DC. A segmentation protocol and MRI atlas of the C57BL/6J mouse neocortex. Neuroimage. 2013;81:196–203.

53. Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage. 2002;15:870–8.

54. Kuan L, Li Y, Lau C, Feng D, Bernard A, Sunkin SM, et al. Neuroinformatics of the Allen Mouse Brain Connectivity Atlas. Methods. 2015;73:4–17.

55. Oh SW, Harris JA, Ng L, Winslow B, Cain N, Mihalas S, et al. A mesoscale connectome of the mouse brain. Nature. 2014;508:207–14.

56. van Kleef ESB, Gaspar P, Bonnin A. Insights into the complex influence of 5-HT signaling on thalamocortical axonal system development. Eur J Neurosci. 2012;35:1563–72.

57. Nieman BJ, Lerch JP, Henkelman RM. Mouse behavioral mutants have neuroimaging abnormalities. Hum Brain Mapp. 2007;28:567–75.

58. Murphy DL, Lesch K-P. Targeting the murine serotonin transporter: insights into human neurobiology. Nat Rev Neurosci. 2008;9:85–96.

59. Ellegood J, Babineau BA, Henkelman RM, Lerch JP, Crawley JN. Neuroanatomical analysis of the BTBR mouse model of autism using magnetic resonance imaging and diffusion tensor imaging. Neuroimage. 2013;70:288–300.

60. Dodero L, Damiano M, Galbusera A, Bifone A, Tsaftsaris SA, Scattoni ML, et al. Neuroimaging evidence of major morpho-anatomical and functional abnormalities in the BTBR T+TF/J mouse model of autism. PLoS One. 2013;8.e76655.

61. Ellegood J, Lerch JP, Henkelman RM. Brain abnormalities in a Neuroligin3 R451C knockin mouse model associated with autism. Autism Res. 2011;4:368–76.

62. Kumar M, Duda JT, Hwang W-T, Kenworthy C, Ittyerah R, Pickup S, et al. High resolution magnetic resonance imaging for characterization of the neureilin-3 knock-in mouse model associated with autism spectrum disorder. PLoS One. 2014;9:e109872.

63. Horev G, Ellegood J, Lerch JP, Son Y-EE, Muthuswamy L, Vogel H, et al. Dosage-dependent phenotypes in models of 16p11.2 lesions found in autism. Proc Natl Acad Sci U S A. 2011;108:17076–81.

64. Portmann T, Yang M, Mao R, Panagiotakos G, Ellegood J, Dolen G, et al. Behavioral abnormalities and circuit defects in the basal ganglia of a mouse model of 16p11.2 deletion syndrome. Cell Rep. 2014;7:1077–1092. https://doi.org/10.1016/j.celrep.2014.03.036. Epub 2014 May 1

65. Persico AM, Minguag E, Moessner R, Hall FS, Revel RS, Sora I, et al. Barrel pattern formation requires serotonin uptake by thalamocortical afferents, and not vesicular monoamine release. J Neurosci. 2001;21:6862–73.

66. Muller CL, Anacker AM, Rogers TD, Goeden N, Keller EH, Forsberg CG, et al. Impact of maternal serotonin transporter genotype on placental serotonin, fetal forebrain serotonin, and neurodevelopment. Neuropsychopharmacology. 2017;42:2427–36.

67. Margolis KG, Li Z, Stevanovic K, Sauman V, Israelyan N, Anderson GM, et al. Serotonin transporter variant drives preventable gastrointestinal abnormalities in development and function. J Clin Invest. 2016;126:2221–35.

68. Suri D, Teixeira CM, Caglostaro MKC, Mahadeva D, Ansorge MS. Monoamine-sensitive developmental periods impacting adult emotional and cognitive behavior. Neuropsychopharmacology. 2015;40:88–112.

69. Brummelte S, Mc Glanaghy E, Bonnin A, Oberlander TF. Developmental changes in serotonin signaling: implications for early brain function, behavior and adaptation. Neuroscience. 2017;342:212–31.

70. Carlson M, Carlson A. A regional study of sex differences in rat brain serotonin. Prog Neuro-Psychopharmacol Biol Psychiatry. 1988;12:533–61.

71. Clayton JA, Collins FS. NIH to balance sex in cell and animal studies. Nature. 2014;509:7500:282–3.

72. Page DT, Kuti OJ, Prestia C, Sur M. Haploinsufficiency for Pten and serotonin transporter cooperatively influences brain size and social behavior. Proc Natl Acad Sci U S A. 2009;106:1989–94.

73. Prasad HC, Steiner JA, Sutcliffe JS, Blakely RD. Enhanced activity of human serotonin transporter variants associated with autism. Philos Trans R Soc Lond Ser B Biol Sci. 2009;364:163–73.